Proactive Investor – Suda Pharmaceuticals Ltd

Dr Michael Baker, CEO of SUDA Pharmaceuticals Ltd (ASX:SUD), speaks to Proactive’s Andrew Scott soon after announcing they’ve received Therapeutics Goods Administration (TGA) approval for their lead product for the treatment of short-term insomnia in adults.

Baker says it’s a significant milestone for the company and is the first product they’ve had approved by a regulator.

”Backing that up we’ve got a number of other products, one I’m particularly excited about, which we’re developing for the treatment of cancer as well as one for migraine and also a couple of products in the medical cannabis space”.